230 related articles for article (PubMed ID: 25124612)
1. Identification of patients with microscopic hematuria who are at greater risk for the presence of bladder tumors using a dedicated questionnaire and point of care urine test--a study by the members of Association of Urooncology, Turkey.
Turkeri L; Mangir N; Gunlusoy B; Yildirim A; Baltaci S; Kaplan M; Bozlu M; Mungan A
Asian Pac J Cancer Prev; 2014; 15(15):6283-6. PubMed ID: 25124612
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
[TBL] [Abstract][Full Text] [Related]
3. Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology.
Odisho AY; Berry AB; Ahmad AE; Cooperberg MR; Carroll PR; Konety BR
Eur Urol; 2013 May; 63(5):936-40. PubMed ID: 22521093
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of a urine-based tumor marker for screening lower urinary tract in low-risk patients with asymptomatic microscopic hematuria.
Sagnak L; Ersoy H; Gucuk O; Ozok U; Topaloglu H
Urol Int; 2011; 87(1):35-41. PubMed ID: 21654152
[TBL] [Abstract][Full Text] [Related]
5. Role of urinary NMP-22 combined with urine cytology in follow-up surveillance of recurring superficial bladder urothelial carcinoma.
Mansoor I; Calam RR; Al-Khafaji B
Anal Quant Cytol Histol; 2008 Feb; 30(1):25-32. PubMed ID: 18459584
[TBL] [Abstract][Full Text] [Related]
6. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection.
Lotan Y; Shariat SF;
BJU Int; 2008 Jun; 101(11):1362-7. PubMed ID: 18284410
[TBL] [Abstract][Full Text] [Related]
7. Utility of urine cytology in the workup of asymptomatic microscopic hematuria in low-risk patients.
Feifer AH; Steinberg J; Tanguay S; Aprikian AG; Brimo F; Kassouf W
Urology; 2010 Jun; 75(6):1278-82. PubMed ID: 20138655
[TBL] [Abstract][Full Text] [Related]
8. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
[TBL] [Abstract][Full Text] [Related]
9. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
10. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.
Smrkolj T; Mihelič M; Sedlar A; Sterle I; Osredkar J; Sedmak B
Clin Chem Lab Med; 2011 Feb; 49(2):311-6. PubMed ID: 21118051
[TBL] [Abstract][Full Text] [Related]
11. Use of the nuclear matrix protein 22 Bladder Chek test™ in the diagnosis of residual urothelial cancer before a second transurethral resection of bladder cancer.
Balci M; Tuncel A; Guzel O; Aslan Y; Sezgin T; Bilgin O; Senel C; Atan A
Int Urol Nephrol; 2015 Mar; 47(3):473-7. PubMed ID: 25649031
[TBL] [Abstract][Full Text] [Related]
12. [Can the combination of bladder ultrasonography and urinary cytodiagnosis replace cystoscopy in the diagnosis and follow-up of tumors of the bladder?].
Cariou G; Maaraoui N; Cortesse A
Prog Urol; 1997 Feb; 7(1):51-5. PubMed ID: 9116739
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.
Kehinde EO; Al-Mulla F; Kapila K; Anim JT
Scand J Urol Nephrol; 2011 Mar; 45(2):113-21. PubMed ID: 21091091
[TBL] [Abstract][Full Text] [Related]
15. Prospective external validation of a bladder cancer detection model.
Lotan Y; Svatek RS; Krabbe LM; Xylinas E; Klatte T; Shariat SF
J Urol; 2014 Nov; 192(5):1343-8. PubMed ID: 24859442
[TBL] [Abstract][Full Text] [Related]
16. [NMP-22 test. Is it useful in the follow-up of patients with superficial bladder tumor?].
Pérez García FJ; Eyo A; Escaf Barmadah S; Fernández Gómez JM
Arch Esp Urol; 2002 Dec; 55(10):1201-8. PubMed ID: 12611217
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.
Lekili M; Sener E; Demir MA; Temeltaş G; Müezzinoğlu T; Büyüksu C
Urol Res; 2004 May; 32(2):124-8. PubMed ID: 14685796
[TBL] [Abstract][Full Text] [Related]
18. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.
O'Sullivan P; Sharples K; Dalphin M; Davidson P; Gilling P; Cambridge L; Harvey J; Toro T; Giles N; Luxmanan C; Alves CF; Yoon HS; Hinder V; Masters J; Kennedy-Smith A; Beaven T; Guilford PJ
J Urol; 2012 Sep; 188(3):741-7. PubMed ID: 22818138
[TBL] [Abstract][Full Text] [Related]
19. A noninvasive multianalyte urine-based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuria.
Karnes RJ; Fernandez CA; Shuber AP
Mayo Clin Proc; 2012 Sep; 87(9):835-42. PubMed ID: 22883743
[TBL] [Abstract][Full Text] [Related]
20. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria.
Sarosdy MF; Kahn PR; Ziffer MD; Love WR; Barkin J; Abara EO; Jansz K; Bridge JA; Johansson SL; Persons DL; Gibson JS
J Urol; 2006 Jul; 176(1):44-7. PubMed ID: 16753364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
